{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T12:36:42Z","timestamp":1784205402659,"version":"3.55.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T00:00:00Z","timestamp":1728518400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+\/HER2\u2212 advanced breast cancer (ABC). This study presents the final pre-planned PFS analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In the phase III MONARCH plus study, postmenopausal women in China, India, Brazil, and South Africa with HR+\/HER2\u2212 ABC without prior systemic therapy in an advanced setting (cohort A) or progression on prior ET (cohort B) were randomized (2:1) to abemaciclib (150\u00a0mg twice daily [BID]) or placebo plus: anastrozole (1.0\u00a0mg\/day) or letrozole (2.5\u00a0mg\/day) (cohort A) or fulvestrant (500\u00a0mg on days 1 and 15 of cycle 1 and then on day 1 of each subsequent cycle) (cohort B). The primary endpoint was PFS of cohort A. Secondary endpoints included cohort B PFS (key secondary endpoint), ORR, overall survival (OS), safety, and health-related quality of life (HRQoL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>In cohort A (abemaciclib: <jats:italic toggle=\"yes\">n<\/jats:italic>\u00a0=\u00a0207; placebo: <jats:italic toggle=\"yes\">n<\/jats:italic>\u00a0=\u00a099), abemaciclib plus a non-steroidal aromatase inhibitor improved median PFS <jats:italic toggle=\"yes\">vs<\/jats:italic>. placebo (28.27\u00a0months <jats:italic toggle=\"yes\">vs<\/jats:italic>. 14.73\u00a0months, hazard ratio [HR]: 0.476; 95% confidence interval [95% CI]: 0.348\u20130.649). In cohort B (abemaciclib: <jats:italic toggle=\"yes\">n<\/jats:italic>\u00a0=\u00a0104; placebo: <jats:italic toggle=\"yes\">n<\/jats:italic>\u00a0=\u00a053), abemaciclib plus fulvestrant improved median PFS <jats:italic toggle=\"yes\">vs<\/jats:italic>. placebo (11.41\u00a0months <jats:italic toggle=\"yes\">vs<\/jats:italic>. 5.59\u00a0months, HR: 0.480; 95% CI: 0.322\u20130.715). Abemaciclib numerically improved ORR. Although immature, a trend toward OS benefit with abemaciclib was observed (cohort A: HR: 0.893, 95% CI: 0.553\u20131.443; cohort B: HR: 0.512, 95% CI: 0.281\u20130.931). The most frequent grade \u22653 adverse events in the abemaciclib arms were neutropenia, leukopenia, anemia (both cohorts), and lymphocytopenia (cohort B). Abemaciclib did not cause clinically meaningful changes in patient-reported global health, functioning, or most symptoms <jats:italic toggle=\"yes\">vs<\/jats:italic>. placebo.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Abemaciclib plus ET led to improvements in PFS and ORR, a manageable safety profile, and sustained HRQoL, providing clinical benefit without a high toxicity burden or reduced quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>\n                                 ClinicalTrials.gov (NCT02763566).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003151","type":"journal-article","created":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T14:17:46Z","timestamp":1728569866000},"page":"1477-1486","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer: Final results of the randomized phase III MONARCH plus trial"],"prefix":"10.1097","volume":"138","author":[{"given":"Xichun","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Cancer Hospital of China Medical University\/Liaoning Cancer Hospital, Shenyang, Liaoning 110042, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Peking University Cancer Hospital & Institute 100142, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Breast Disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116023, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue\u2019e","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Pimentel","family":"Oppermann","sequence":"additional","affiliation":[{"name":"Centro de Pesquisa Cl\u00ednica de Oncologia e Hematologia, Hospital M\u00e3e de Deus\/AESC, Porto Alegre, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind Babu","family":"Kanakasetty","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, HCG Hospitals and Kidwai Memorial Institute of Oncology, Bangalore, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA Coccia","family":"Portugal","sequence":"additional","affiliation":[{"name":"Clinical Trial Department, Eastleigh Breast Care Center, Pretoria, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Shanghai 200021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Shanghai 200021, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zefei","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Breast Cancer, Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"R1-20250620","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250620","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/1759-7714.12426","article-title":"Female breast cancer incidence and mortality in China, 2013","volume":"8","author":"Zuo","year":"2017","journal-title":"Thorac Cancer"},{"key":"R3-20250620","doi-asserted-by":"crossref","DOI":"10.1097\/CM9.0000000000003278","article-title":"Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022","author":"Sun","year":"2024","journal-title":"Chin Med J."},{"key":"R4-20250620","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s40265-019-01208-8","article-title":"Advances in endocrine-based therapies for estrogen receptor-positive metastatic breast cancer","volume":"79","author":"Aggelis","year":"2019","journal-title":"Drugs"},{"key":"R5-20250620","first-page":"2315","article-title":"17beta-estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells","volume":"12","author":"Altucci","year":"1996","journal-title":"Oncogene"},{"key":"R6-20250620","first-page":"2077","article-title":"Identification of G1 kinase activity for cdk6, a novel cyclin D partner","volume":"14","author":"Meyerson","year":"1994","journal-title":"Mol Cell Biol"},{"key":"R7-20250620","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/CM9.0000000000002313","article-title":"Prognosis related genes in HER2+ breast cancer based on weighted gene co-expression network analysis","volume":"136","author":"Weng","year":"2023","journal-title":"Chin Med J"},{"key":"R8-20250620","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"R9-20250620","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"R10-20250620","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"R11-20250620","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol"},{"key":"R12-20250620","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1097\/CM9.0000000000002676","article-title":"Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer","volume":"136","author":"Yuan","year":"2023","journal-title":"Chin Med J"},{"key":"R13-20250620","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1097\/CM9.0000000000002240","article-title":"Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: Real-world data in the Han population","volume":"135","author":"Mo","year":"2022","journal-title":"Chin Med J"},{"key":"R14-20250620","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: A CDK4\/6 inhibitor for the treatment of HR+\/HER2- advanced breast cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"R15-20250620","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1535-7163.MCT-17-0290","article-title":"Preclinical activity of abemaciclib alone or in combination with antimitotic and targeted therapies in breast cancer","volume":"17","author":"O\u2019Brien","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"R16-20250620","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: A randomized clinical trial","volume":"6","author":"Sledge","year":"2020","journal-title":"JAMA Oncol"},{"key":"R17-20250620","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: In-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest New Drugs"},{"key":"R18-20250620","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"R19-20250620","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","article-title":"MONARCH 3 final PFS: A randomized study of abemaciclib as initial therapy for advanced breast cancer","volume":"5","author":"Johnston","year":"2019","journal-title":"NPJ Breast Cancer"},{"key":"R21-20250620","doi-asserted-by":"crossref","first-page":"1758835920963925","DOI":"10.1177\/1758835920963925","article-title":"MONARCH plus: Abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: The multinational randomized phase III study","volume":"12","author":"Zhang","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 2","key":"R22-20250620","doi-asserted-by":"crossref","first-page":"S427","DOI":"10.1016\/j.jval.2020.08.175","article-title":"PCN38 health-related quality of life (QOL) in monarch PLUS: A phase 3 trial of abemaciclib PLUS nonsteroidal aromatase inhibitor (NSAI) or fulvestrant for women with HR+\/HER2- advanced breast cancer (ABC)","volume":"23","author":"Hu","year":"2020","journal-title":"Value Health"},{"key":"R23-20250620","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"R26-20250620","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.suponc.2010.12.004","article-title":"Estimating minimally important differences for the worst pain rating of the brief pain inventory-short form","volume":"9","author":"Mathias","year":"2011","journal-title":"J Support Oncol"},{"key":"R27-20250620","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"R28-20250620","first-page":"1","article-title":"Disparities in breast, lung, and cervical cancer trials worldwide","volume":"4","author":"Ramaswami","year":"2018","journal-title":"J Glob Oncol"},{"key":"R29-20250620","doi-asserted-by":"crossref","first-page":"57301","DOI":"10.18632\/oncotarget.10254","article-title":"Fulvestrant 500\u00a0mg vs 250\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: A randomized, double-blind registrational trial in China","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"R30-20250620","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1097\/CM9.0000000000002831","article-title":"A multicenter study of the clinicopathological characteristics and a risk prediction model of early-stage breast cancer with hormone receptor-positive\/human epidermal growth factor receptor 2-low expression","volume":"136","author":"Xin","year":"2023","journal-title":"Chin Med J"},{"issue":"Suppl 7","key":"R31-20250620","doi-asserted-by":"crossref","first-page":"S1384","DOI":"10.1016\/j.annonc.2022.08.009","article-title":"LBA15\u2013MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)","volume":"33","author":"Goetz","year":"2022","journal-title":"Ann Oncol"},{"key":"R32-20250620","doi-asserted-by":"crossref","first-page":"822","DOI":"10.20892\/j.issn.2095-3941.2019.0321","article-title":"Breast cancer screening guideline for Chinese women","volume":"16","year":"2019","journal-title":"Cancer Biol Med"},{"key":"R33-20250620","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/CM9.0000000000002635","article-title":"Clinicopathological features and prognoses of very young patients (\u226435 years) with breast cancer: A retrospective population-based study in China","volume":"136","author":"Ye","year":"2023","journal-title":"Chin Med J"},{"key":"R34-20250620","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.3390\/ijms21176400","article-title":"Progression-free survival and overall survival of CDK 4\/6 inhibitors plus endocrine therapy in metastatic breast cancer: A systematic review and meta-analysis","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R35-20250620","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1634\/theoncologist.2019-0551","article-title":"Health-related quality of life in MONARCH 2: Abemaciclib plus fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy","volume":"25","author":"Kaufman","year":"2020","journal-title":"Oncologist"},{"key":"R36-20250620","doi-asserted-by":"crossref","first-page":"e1346","DOI":"10.1634\/theoncologist.2020-0084","article-title":"Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2- advanced breast cancer","volume":"25","author":"Goetz","year":"2020","journal-title":"Oncologist"},{"key":"R37-20250620","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/AJP.0b013e3181f3f667","article-title":"Fear of pain in patients with advanced cancer or in patients with chronic noncancer pain","volume":"27","author":"Lemay","year":"2011","journal-title":"Clin J Pain"},{"key":"R38-20250620","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1586\/14737167.2014.864560","article-title":"Predictive factors of overall quality of life in advanced cancer patients using EORTC QLQ-C30","volume":"14","author":"Cramarossa","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T04:00:41Z","timestamp":1750392041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CM9.0000000000003151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003151","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]},"assertion":[{"value":"2024-06-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}